|
|
AstraZeneca PLC figure parmi les principaux groupes pharmaceutiques mondiaux. Le CA par domaine thérapeutique se répartit comme suit :
- oncologie (36,8%) ;
- maladies respiratoires (22,9%) ;
- maladies cardio-vasculaires, rénales et métaboliques (18,6%) ;
- autres (21,7%) : maladies inflammatoires et auto-immunes, maladies neurologiques, maladies gastro-intestinales et maladies infectieuses.
La répartition géographique du CA est la suivante : Royaume Uni (2%), Europe continentale (16,5%), Amérique (38,3%) et Afrique-Asie-Australie (43,2%).
Nombre d'employés : 70 600 personnes.
|
|
|
| 2018 | 2019 | Delta | | GBP (en Millions) | % | GBP (en Millions) | % | | Oncology | 4 521 | 27.3% | 6 794 | 35.5% | +50.28% | | Cardiovascular, Renal & Metabolism | 5 032 | 30.4% | 5 413 | 28.3% | +7.57% | | Respiratory | 3 683 | 22.2% | 4 226 | 22.1% | +14.74% | | Other Diseases | 2 550 | 15.4% | 2 039 | 10.7% | -20.04% | | Externalisation Revenue | 780,71 | 4.7% | 641,98 | 3.4% | -17.77% |
|
|
|
| 2019 | | GBP (en Millions) | % | | United States | 6 308 | 33% | | China | 3 815 | 20% | | Japan | 1 977 | 10.3% | | United Kingdom | 1 428 | 7.5% | | Other Asia, Africa and Australasia | 1 112 | 5.8% | | Other Continental Europe | 1 012 | 5.3% | | Sweden | 653,74 | 3.4% | | Other Americas | 638,06 | 3.3% | | Germany | 551,84 | 2.9% | | France | 453,07 | 2.4% |
|
| Dirigeants et Administrateurs |
|
|
|
|
|
| Vote  | Nombre | Flottant | Autocontrôle | Flottant Total |
| Action A |
1 |
1 312 668 724 |
1 256 822 435 |
95.7% |
0 |
0.0% |
95.7% |
|
| Actionnaires | |
|
| Nom | Actions | % | | Investor AB (Investment Company) | 51 587 810 |
3,93% | | BlackRock Investment Management (UK) Ltd. | 42 170 900 |
3,21% | | Capital Research & Management Co. (World Investors) | 41 526 368 |
3,16% | | Wellington Management Co. LLP | 38 725 550 |
2,95% | | The Vanguard Group, Inc. | 37 200 514 |
2,83% | | Norges Bank Investment Management | 31 680 000 |
2,41% | | BlackRock Fund Advisors | 24 452 643 |
1,86% | | BlackRock Advisors (UK) Ltd. | 16 769 205 |
1,28% | | Fidelity Management & Research Co. LLC | 15 972 842 |
1,22% | | SSgA Funds Management, Inc. | 13 880 589 |
1,06% |
| Nom | Actions | % | | Investor AB (Investment Company) | 190 171 620 |
7,24% | | Wellington Management Co. LLP | 52 093 683 |
1,98% | | PRIMECAP Management Co. | 51 498 061 |
1,96% | | Fidelity Management & Research Co. LLC | 42 939 426 |
1,64% | | Jennison Associates LLC | 31 035 458 |
1,18% | | Capital Research & Management Co. (International Investors) | 29 249 466 |
1,11% | | Fisher Asset Management LLC | 17 342 680 |
0,66% | | T. Rowe Price Associates, Inc. (Investment Management) | 15 650 130 |
0,60% | | Capital Research & Management Co. | 14 965 800 |
0,57% | | Dodge & Cox | 14 821 346 |
0,56% |
|
|
|
|
- - Main Market - OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50 |
|
|
|
|
| - Code Bloomberg : |
AZN:LN |
| - Code Reuters : |
AZN.L |
| - Code Datastream : |
AZN |
|
|
|
AstraZeneca PLC Cambridge Biomedical Campus 1 Francis Crick Avenue CB2 0AA Cambridge, Cambridgeshire Téléphone : +44 (0)20 3749 5000 Fax : +44 (0)20 7604 8151 Internet : http://www.astrazeneca.com |
|
|
|
Apple, LVMH et Tesla au (copieux) menu de la semaine |
Connexions : AstraZeneca PLC |
Canada
Deutschland
España
Italia
Schweiz (DE)
United Kingdom
United States
bourse
Rapport
